Sii Investments Inc. WI boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 34.8% during the second quarter, Holdings Channel reports. The firm owned 6,107 shares of the medical research company’s stock after buying an additional 1,576 shares during the period. Sii Investments Inc. WI’s holdings in Amgen were worth $930,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. Bank of Montreal Can bought a new stake in shares of Amgen during the second quarter valued at approximately $383,036,000. Wellington Management Group LLP boosted its stake in shares of Amgen by 16.0% in the first quarter. Wellington Management Group LLP now owns 13,544,922 shares of the medical research company’s stock valued at $2,030,789,000 after buying an additional 1,864,688 shares during the last quarter. Nordea Investment Management AB boosted its stake in shares of Amgen by 37.1% in the second quarter. Nordea Investment Management AB now owns 5,719,168 shares of the medical research company’s stock valued at $870,171,000 after buying an additional 1,547,099 shares during the last quarter. Emerald Acquisition Ltd. bought a new stake in shares of Amgen during the second quarter valued at approximately $194,466,000. Finally, NN Investment Partners Holdings N.V. bought a new stake in shares of Amgen during the first quarter valued at approximately $113,507,000. Institutional investors own 79.15% of the company’s stock.
Amgen Inc. (NASDAQ:AMGN) traded down 0.60% during midday trading on Thursday, reaching $168.70. 654,934 shares of the company were exchanged. The company has a market capitalization of $126.25 billion, a PE ratio of 17.26 and a beta of 0.87. The firm has a 50-day moving average price of $172.00 and a 200-day moving average price of $160.83. Amgen Inc. has a 52 week low of $135.64 and a 52 week high of $176.85.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, beating analysts’ consensus estimates of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The business earned $5.69 billion during the quarter, compared to analysts’ expectations of $5.58 billion. During the same period last year, the business earned $2.57 earnings per share. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. Equities research analysts anticipate that Amgen Inc. will post $11.36 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were issued a $1.00 dividend. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.36%. The ex-dividend date of this dividend was Monday, August 15th. Amgen’s dividend payout ratio (DPR) is currently 40.90%.
AMGN has been the topic of several research analyst reports. Vetr cut shares of Amgen from a “hold” rating to a “sell” rating and set a $166.35 price target on the stock. in a research note on Monday, August 1st. Goldman Sachs Group Inc. restated a “buy” rating and issued a $204.00 target price on shares of Amgen in a report on Thursday, September 8th. Cowen and Company restated a “buy” rating on shares of Amgen in a report on Monday, September 19th. Jefferies Group restated a “buy” rating and issued a $187.00 target price on shares of Amgen in a report on Wednesday, July 13th. Finally, Piper Jaffray Cos. restated a “buy” rating and issued a $193.00 target price on shares of Amgen in a report on Thursday, July 28th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the stock. Amgen has an average rating of “Buy” and an average target price of $184.51.
In related news, VP Annette Louise Such sold 3,000 shares of Amgen stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.20% of the stock is currently owned by corporate insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.